ArticlebioRxiv : the preprint server for biology2024
Rational design of HER2-targeted combination therapies to reverse drug resistance in fibroblast-protected HER2+ breast cancer cells.
Matthew D Poskus et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.